Verrica (VRCA) CEO awarded 512,269 options with $15 and $25 vesting hurdles
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Verrica Pharmaceuticals CEO and President Jayson Rieger was granted an employee stock option covering 512,269 shares of common stock at an exercise price of $8.21 per share. The option expires on December 23, 2035 and vests in two tranches tied to share-price hurdles.
Half of the option vests if Verrica’s Nasdaq closing price reaches at least $15.00 per share, and the other half vests if it reaches at least $25.00 per share, in each case subject to his continued service. The grant was originally approved in December 2025 and became effective after shareholders approved an amendment to the 2018 Equity Incentive Plan on June 5, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Rieger Jayson
Role
CEO and President
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 512,269 | $0.00 | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 512,269 shares (Direct, null)
Footnotes (1)
- The option grant was approved by a committee of the Issuer's board of directors on December 23, 2025, subject to shareholder approval of an amendment to the Issuer's 2018 Equity Incentive Plan under which the option was granted. The Issuer's shareholders approved the amendment on June 5, 2026. 50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $15.00, and 50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $25.00, subject to the Reporting Person's continuous service through each such vesting date.
Key Figures
Option grant size: 512,269 shares
Exercise price: $8.21 per share
Expiration date: December 23, 2035
+3 more
6 metrics
Option grant size
512,269 shares
Employee stock option granted to CEO
Exercise price
$8.21 per share
Strike price of granted option
Expiration date
December 23, 2035
Option term end
Post-grant derivative holdings
512,269 derivatives
Total options held after transaction
First vesting hurdle
$15.00 share price
50% of option vests at this Nasdaq close
Second vesting hurdle
$25.00 share price
Remaining 50% vests at this Nasdaq close
Key Terms
Employee Stock Option, 2018 Equity Incentive Plan, vesting, closing sales price
4 terms
Employee Stock Option financial
"security_title: Employee Stock Option (right to buy)"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
2018 Equity Incentive Plan financial
"amendment to the Issuer's 2018 Equity Incentive Plan under which the option was granted"
vesting financial
"50% of the total shares subject to the option shall vest on the date that the closing sales price per share"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
closing sales price financial
"on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $15.00"
FAQ
What did Verrica Pharmaceuticals (VRCA) CEO Jayson Rieger report in this Form 4?
Jayson Rieger reported receiving an employee stock option for 512,269 shares of Verrica common stock at a $8.21 exercise price. The option is compensation, not an open-market trade, and is subject to specific stock-price vesting conditions and continued service requirements.
What are the key terms of Jayson Rieger’s new Verrica (VRCA) stock option?
The option covers 512,269 shares at a fixed exercise price of $8.21 per share and expires on December 23, 2035. It was granted under Verrica’s 2018 Equity Incentive Plan, following shareholder approval of an amendment on June 5, 2026.
How does the vesting of the Verrica (VRCA) CEO’s stock option work?
Vesting is based on Verrica’s share price. 50% of the option vests once the Nasdaq closing price reaches at least $15.00 per share, and the remaining 50% vests when it reaches at least $25.00, assuming Jayson Rieger remains in continuous service.
Does this Verrica (VRCA) Form 4 show any insider stock sales or purchases?
No open-market sales or purchases are reported. The filing shows a grant of an employee stock option to CEO Jayson Rieger, categorized as a grant/award acquisition, with no shares bought or sold in the market in this transaction.
What is Jayson Rieger’s option position in Verrica (VRCA) after this transaction?
After the reported grant, Jayson Rieger holds 512,269 derivative securities representing options on an equal number of Verrica common shares. All of these options relate to this single grant and are held in direct ownership according to the filing details.